Search

Your search keyword '"Schultz, Henrik"' showing total 152 results
Start Over Author "Schultz, Henrik"
152 results on '"Schultz, Henrik"'

14. Walking

Author

Schultz, Henrik, primary and Etteger, Rudi van, additional

Published
2016
Full Text
View/download PDF

15. Green Fingers for Climate-Resilient Cities – Connecting Processes of Landscape Planning and Designing with Co-Creation

Author

Schultz, Henrik, von Dressler, Hubertus, and Nikolaus, Lea

Abstract

Taking the transdisciplinary research study “Green fingers for a climate resilient city”, funded by the German Ministry of education and research (BMBF), as an example, this paper follows the hypothesis that processes of landscape planning and designing multifunctional green spaces and processes of co-creation need to be combined to stimulate climate resilient city transformation. The findings are that efforts to combine these processes benefit from making complex climate-resilient city planning accessible for people of different professional backgrounds. The paper showcases how storytelling (Schmidt 2019), mapping (Langner 2009) and guided walks (Schultz 2019) are means to mutually engage with, perceive and understand multifunctional green spaces, inspire ownership, and build capacity for the city’s climate-resilient transformation.

Published
2022
Full Text
View/download PDF

16. Additional file 1 of DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome���including in elderly patients

Author

Bady, Pierre, Marosi, Christine, Weller, Michael, Gr��nberg, Bj��rn H., Schultz, Henrik, Taphoorn, Martin J. B., Gijtenbeek, Johanna M. M., van den Bent, Martin J., von Deimling, Andreas, Stupp, Roger, Malmstr��m, Annika, and Hegi, Monika E.

Abstract

Additional file. 1. Table S1.Description of full EORTC/NCIC & LN-Pilot and Nordic datasets. Table S2. DNA methylation associated with patient age. Table S3. Associations of methylation based entropy by genomic region and GBM classification. Table S4. Functional CpGs located on DDR genes, associated with Age Acceleration. Table S5. Functional CpGs located on DDR genes, associated with GBM classification. Fig. S1 Methylation-based classification of tumors of all patients from EORTC/NCIC & LN-Pilot and Nordic studies. Fig. S2 Impact of sample purity on measures of DNAm age acceleration, and HM entropy. Fig. S3 Pathways associated with functional methylation related to DNAm age acceleration and GBM classification. Fig. S4 CDKN2A CNV and DNAm age acceleration.

Published
2022
Full Text
View/download PDF

17. DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome - including in elderly patients

Author

Bady, Pierre, primary, Marosi, Christine, additional, Weller, Michael, additional, Grønberg, Bjørn H., additional, Schultz, Henrik, additional, Taphoorn, Martin J. B., additional, Gijtenbeek, Johanna M. M., additional, van den Bent, Martin J., additional, Deimling, Andreas von, additional, Stupp, Roger, additional, Malmström, Annika, additional, and Hegi, Monika E., additional

Published
2022
Full Text
View/download PDF

24. Planning for the new European metropolis: functions, politics, and symbols/Metropolitan regions: functional relations between the core and the periphery/Business investment decisions and spatial planning policy/Metropolitan challenges, political responsibilities/Spatial imaginaries, urban dynamics and political community/Capacity-building in the city region: creating common spaces/Which challenges for today's European metropolitan spaces?

Author

Salet, Willem, primary, Vermeulen, Rick, additional, Savini, Federico, additional, Dembski, Sebastian, additional, Thierstein, Alain, additional, Nears, Peter, additional, Vink, Bart, additional, Healey, Patsy, additional, Stein, Ursula, additional, Schultz, Henrik, additional, and Salet, Willem, additional

Published
2015
Full Text
View/download PDF

28. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme:A randomized phase II study

Author

Hofland, Kenneth F, Hansen, Steinbjørn, Sorensen, Morten, Engelholm, Silke, Schultz, Henrik P, Muhic, Aida, Grunnet, Kirsten, Ask, Anders, Costa, Junia C, Kristiansen, Charlotte, Thomsen, Carsten, Poulsen, Hans Skovgaard, Lassen, Ulrik, Hofland, Kenneth F, Hansen, Steinbjørn, Sorensen, Morten, Engelholm, Silke, Schultz, Henrik P, Muhic, Aida, Grunnet, Kirsten, Ask, Anders, Costa, Junia C, Kristiansen, Charlotte, Thomsen, Carsten, Poulsen, Hans Skovgaard, and Lassen, Ulrik

Abstract

BACKGROUND: Surgery followed by radiotherapy and concomitant and adjuvant temozolomide is standard therapy in newly diagnosed glioblastoma multiforme (GBM). Bevacizumab combined with irinotecan produces impressive response rates in recurrent GBM. In a randomized phase II study, we investigated the efficacy of neoadjuvant bevacizumab combined with irinotecan (Bev-Iri) versus bevacizumab combined with temozolomide (Bev-Tem) before, during and after radiotherapy in newly diagnosed GBM.MATERIAL AND METHODS: After surgery, patients were randomized to Bev-Iri or Bev-Tem for eight weeks, followed by standard radiotherapy (60 Gy/30 fractions) and concomitant Bev-Iri or Bev-Tem followed by adjuvant Bev-Iri or Bev-Tem for another eight weeks. Bev-Iri: Bevacizumab and irinotecan were given every 14 days before, during and after radiotherapy. Bev-Tem: Bevacizumab was given as in Bev-Iri and temozolomide was given for five days every four weeks before and after radiotherapy and once daily during radiotherapy. The primary endpoint was response after neoadjuvant chemotherapy and a pre-specified response rate of 30% or more was considered of interest for future studies. Secondary endpoints were progression-free survival (PFS) and toxicity.RESULTS: The response rate was 32% (95% CI 17-51%) for Bev-Tem (n = 32) and 23% (95% CI 9-44%) for Bev-Iri (n = 31) (p = 0.56). Median PFS was 7.7 and 7.3 months for Bev-Tem and Bev-Iri, respectively. Hematological toxicity was more frequent with Bev-Tem including one death from febrile neutropenia whereas non-hematological toxicity was manageable.CONCLUSIONS: Only the Bev-Tem arm met the pre-specified level of activity of interest. Our results did not indicate any benefit from Bev-Iri in first-line therapy as opposed to Bev-Tem in terms of response and PFS.

Published
2014

31. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy

Author

Møller, Søren, Grunnet, Kirsten, Hansen, Steinbjørn, Schultz, Henrik Pagh, Holmberg, Mats, Mau-Sørensen, Morten, Poulsen, Hans S, Lassen, Ulrik, Møller, Søren, Grunnet, Kirsten, Hansen, Steinbjørn, Schultz, Henrik Pagh, Holmberg, Mats, Mau-Sørensen, Morten, Poulsen, Hans S, and Lassen, Ulrik

Abstract

The combination of irinotecan and bevacizumab has shown efficacy in the treatment of recurrent glioblastoma multiforme (GBM). A prospective, phase II study of 85 patients with various recurrent brain tumors was carried out. Primary endpoints were progression free survival (PFS) and response rate.

Published
2012

32. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Author

Reardon, David D.A., Dresemann, Gregor, Taillibert, Sophie, Campone, Mario, van den Bent, Martin M.J., Clement, Paul M J P., Blomquist, Erik, Gordower, Laurence, Schultz, Henrik, Raizer, Jeffrey, Hau, Peter, Easaw, Jacob, Gil, Miguel, Tonn, Jörg Christian J., Gijtenbeek, Anja M M A., Schlegel, Uwe, Bergstrom, Per, Green, Sylvan S.B., Weir, Alva Bowen A., Nikolova, Zariana, Reardon, David D.A., Dresemann, Gregor, Taillibert, Sophie, Campone, Mario, van den Bent, Martin M.J., Clement, Paul M J P., Blomquist, Erik, Gordower, Laurence, Schultz, Henrik, Raizer, Jeffrey, Hau, Peter, Easaw, Jacob, Gil, Miguel, Tonn, Jörg Christian J., Gijtenbeek, Anja M M A., Schlegel, Uwe, Bergstrom, Per, Green, Sylvan S.B., Weir, Alva Bowen A., and Nikolova, Zariana

Abstract

Background: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). Methods: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). Results: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). Conclusions: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity. © 2009 Cancer Research UK., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2009

33. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

Author

Hofland, Kenneth F., primary, Hansen, Steinbjørn, additional, Sorensen, Morten, additional, Engelholm, Silke, additional, Schultz, Henrik P., additional, Muhic, Aida, additional, Grunnet, Kirsten, additional, Ask, Anders, additional, Costa, Junia C., additional, Kristiansen, Charlotte, additional, Thomsen, Carsten, additional, Poulsen, Hans Skovgaard, additional, and Lassen, Ulrik, additional

Published
2014
Full Text
View/download PDF

42. Optic gliomas: A retrospective analysis of 50 cases

Author

Khafaga, Yasser, primary, Hassounah, Maher, additional, Kandil, Alaa, additional, Kanaan, Imaduddin, additional, Allam, Ayman, additional, El Husseiny, Gamal, additional, Kofide, Amani, additional, Belal, Abdulaziz, additional, Al Shabanah, Mohammed, additional, Schultz, Henrik, additional, and Jenkin, Derek, additional

Published
2003
Full Text
View/download PDF

44. Malignant Fibrous Histiocytoma

Author

Belal, Abdelaziz, primary, Kandil, Alaa, additional, Allam, Ayman, additional, Khafaga, Yasser, additional, El-Husseiny, Gamal, additional, El-Enbaby, Ashraf, additional, Memon, Mohamed, additional, Younge, Derek, additional, Moreau, Paul, additional, Gray, Alan, additional, and Schultz, Henrik, additional

Published
2002
Full Text
View/download PDF

45. Primary Thyroid Lymphoma

Author

Belal, Abdel Aziz, primary, Allam, Ayman, additional, Kandil, Alaa, additional, Husseiny, Gamal El, additional, Khafaga, Yasser, additional, Rajhi, Nasser Al, additional, Ahmed, Gamal, additional, Gray, Alan, additional, Ajarim, Dahish, additional, Schultz, Henrik, additional, and Ezzat, Adnan, additional

Published
2001
Full Text
View/download PDF

47. Prognostic factors for medulloblastoma

Author

Jenkin, Derek, primary, Shabanah, Mohamed Al, additional, Shail, Essam Al, additional, Gray, Alan, additional, Hassounah, Maher, additional, Khafaga, Yasser, additional, Kofide, Amani, additional, Mustafa, Mahmoud, additional, and Schultz, Henrik, additional

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results